Upcoming event

Decision-making and management strategies for patients with bilateral synchronous non-metastatic renal masses: Insights from a multi-centre European dataset

The detrimental effect of frailty status on renal function recovery after partial nephrectomy – long-term results from a prospective surgical cohort

What happens to the preserved renal parenchyma after clamped partial nephrectomy?

European Urology, May 2022

Prospective evaluation of circulating tumor DNA (ctDNA) in detecting early progression on immune checkpoint inhibitors in patients with advanced genitourinary cancers

Machine learning approach to predict pT3a upstaging of clinically localized renal cell carcinoma and oncological outcomes after surgery (UroCCR 15 study)

Surgical delay after biopsy and risk of upstaging for clinical T1a renal cell carcinoma

Improving decision-making for cytoreductive nephrectomy by evaluating pre-surgical radiographic tumor characteristics

Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial

Nature Medicine, February 2022

European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update

European Urology, March 2022

Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK)

ORCHID: A phase II study of olaparib in metastatic renal cell carcinoma patients harboring a BAP1 or other DNA repair gene mutations

SWOG S1931 (PROBE): Phase III randomized trial of immune checkpoint inhibitor (ICI) combination regimen with or without cytoreductive nephrectomy (CN) in advanced renal cancer

PreviousNext